Keros Therapeutics (NASDAQ:KROS) Director Julius Knowles Sells 2,625 Shares

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Julius Knowles sold 2,625 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the sale, the director directly owned 10,958 shares in the company, valued at approximately $117,579.34. The trade was a 19.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Trading Down 2.9%

Shares of NASDAQ:KROS opened at $10.00 on Tuesday. The stock’s 50-day moving average price is $11.31 and its two-hundred day moving average price is $15.10. Keros Therapeutics, Inc. has a 12-month low of $9.79 and a 12-month high of $22.55. The firm has a market cap of $197.90 million, a price-to-earnings ratio of -3.32 and a beta of 0.94.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). The firm had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%. As a group, research analysts forecast that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC acquired a new stake in Keros Therapeutics in the first quarter valued at approximately $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Keros Therapeutics by 15.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock valued at $227,000 after acquiring an additional 2,982 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Keros Therapeutics by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after acquiring an additional 205,022 shares in the last quarter. Creative Planning grew its position in Keros Therapeutics by 40.2% in the second quarter. Creative Planning now owns 24,226 shares of the company’s stock valued at $323,000 after acquiring an additional 6,948 shares in the last quarter. Finally, Rhumbline Advisers grew its position in Keros Therapeutics by 16.0% in the second quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock valued at $692,000 after acquiring an additional 7,146 shares in the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on KROS. Weiss Ratings downgraded Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Wells Fargo & Company cut their price objective on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. Finally, Wall Street Zen downgraded Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $20.40.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.